Related Experiment Video
Updated: Jun 4, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Erythropoietin for neonatal brain injury: opportunity and challenge
1Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Insights
Erythropoietin (EPO) shows promise for neonatal brain injury, but its mechanisms, optimal dosing, and safety require further research. This review explores EPO
Area of Science:
- Neonatal Neurology
- Neuroprotection
- Biochemistry
Background:
- Neonatal brain injury from hypoxia-ischemia and prematurity presents significant treatment challenges.
- Current treatments like hypothermia offer incomplete neuroprotection for hypoxic-ischemic encephalopathy (HIE).
- Erythropoietin (EPO) exhibits neuroprotective properties in neonatal models and clinical trials for HIE.
Purpose of the Study:
- To review the potential mechanisms of EPO's neuroprotection in neonates.
- To discuss recent clinical findings and potential complications associated with EPO use.
- To explore optimal EPO dosing, administration, and novel EPO mimetics.
Main Methods:
- Literature review of experimental models and clinical trials.
- Analysis of reported mechanisms, dosing strategies, and toxicity data.
- Discussion of future directions, including EPO mimetics.
Main Results:
- EPO demonstrates neuroprotective effects in various neonatal injury models.
- Clinical trial data for HIE show potential benefits but highlight inconsistencies.
- Concerns exist regarding optimal dosing, administration routes, and potential adverse effects.
Conclusions:
- EPO holds promise as a neuroprotective agent for neonatal brain injury.
- Further research is critical to establish consistent efficacy, safety, and optimal therapeutic protocols.
- Novel EPO mimetics may offer improved therapeutic profiles.
Abstract:
Neonatal brain injury, caused by perinatal hypoxia-ischemia and extreme prematurity, remains a great challenge for prevention and treatment. There is no effective treatment for term hypoxic-ischemic encephalopathy (HIE) except hypothermia which by itself does not afford complete neuroprotection. Erythropoietin (EPO), a pleiotropic cytokine, has neuroprotective effects in a series of neonatal experimental models and recent clinical trials of HIE. However, the mechanisms, dosing, and the toxicity of EPO in these settings are inconsistently reported. This review will focus on the possible mechanisms, recent clinical advances and potential complications of EPO used in research and the clinic. In addition, optimal dose and administrative routes of EPO, and novel EPO mimetics will be discussed.
Related Concept Videos
Traumatic Brain Injury l: Introduction
Spinal Cord Injury ll: Pathophysiology
Neurogenesis and Regeneration of Nervous Tissue
Erythropoiesis

